A noninvasive technique for monitoring response to chemotherapy in human acute leukemia

Posey, L.; Rainey, John M.; Vial, R; Ryan, Donna H.; Bickers, John H.; Morgan, Lee Roy; Samuels, Monroe S.; Hull, Edgar

doi:10.1002/1097-0142(197909)44:3<873::aid-cncr2820440313>3.0.co;2-t

Cited by 10 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the activities of various enzymes such as fucosyl transferase (Khilanani et al 1977), sialyltranferase (Lin et al 1981), adenosine deaminase (Sako et al 1981) and arylsulf atase (Posey et al 1979) were investigated to examine proliferation of leukemic cells. It has never been demonstrated clinically, however, that the activities of these enzymes can serve as the criteria for early detection of relapse.…”

Section: Discussionmentioning

confidence: 99%

Prognostic evaluation of early detection of relapse in adult acute leukemia.

Kawamura

Tohno

Ichiro

et al. 1984

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

A criterion was established in a previous study to detect the relapse of adult acute leukemia in its early stage, i.e., when lymphocytes in peripheral blood increased over 45% of the leukocytes during the maintenance therapy, bone marrow puncture was immediately performed to examine the leukemic cells. By this criterion the relapse was detected earlier than by other criteria. To study the effect of early detection of the relapse in adult acute leukemia on the results, the second remission rate and the survival time were compared between the following groups. Group I consisted of 11 patients, whose relapse was determined by our criterion. Group II consisted of 8 patients whose relapse was determined by the appearance of leukemic cells in peripheral blood. The second remission was accomplished in 7 of 11 patients in Group 1(64%) and in 1 of 8 in Group 11 (13%) (p <0.05). The mean (+s.D.) duration of complete remission in Group I was 9.7+ 7.8 months and not significantly longer than the value in Group 11(5.3 +3.9 months). The interval from relapse to death was 10.3±5.9 and 6.1±3.8 months in Groups I and II, respectively. The interval from relapse to death of 7 patients who accomplished the second remission in Group I was 12.5+5.5 months. This interval was significantly longer than in Group II (p <0.02). The mean survival time was 22.2± 9.6 months in Group I and 13+ 2.5 months in Group II. The mean survival time of 7 patients accomplished the second remission in Group I was 26. 7±9.4 months which was significantly longer than in Group II (p <0.01). The results showed that our criterion to detect relapse in the early stage was effective for prolongation of the survival time in adult acute leukemia. early detection of relapse ; adult acute leukemia ; percentage of lymphocyte ; survival time ; second remission rateThe complete remission rate in adult acute leukemia in Japan has recently been over 80% owing to the development of antileukemic agents and improved combination chemotherapy. Next important problems in control of acute leukemia in adults would be the duration of maintenance therapy, the time of second

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic evaluation of early detection of relapse in adult acute leukemia.

Kawamura

Tohno

Ichiro

et al. 1984

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…According to one study, this enzyme excretion is a useful indicator of response to antileukemic therapy [2]. Despite the simplicity, noninvasive character, and reliability of this test, few attempts have been made to employ this procedure in the routine management of leukemia.…”

Section: Introductionmentioning

confidence: 99%

Aryl sulfatase a in acute nonlymphocytic leukemia

et al. 1982

View full text Add to dashboard Cite

To ascertain whether estimation of urinary aryl sulfatase A (ASA) is a reliable noninvasive technique for monitoring disease activity in adult acute nonlymphocytic leukemia, we studied the excretion pattern of this enzyme during active disease, partial remission, and complete remission in ten patients and compared the results with those of ten healthy volunteers. There was no significant difference in enzyme excretion between complete remission cases and the control group. Patients with partial remission and active disease had significantly different urinary enzyme levels from each other and from the control and complete remission groups. Estimation of urinary ASA is a useful noninvasive method of monitoring disease activity in adult acute nonlymphocytic leukemia.

show abstract

“…The activity levels of lysosomal arylsulfatases A and B were shown to be elevated in leukocytes (Tanaka et al 1962; Uehara et al 1983) and urine (Dzialoszynski 1957) from CML patients. The urinary activity levels of the enzymes in patients with leukemia were changed in response to disease state, providing a possible noninvasive method of monitoring the disease state (Posey et al 1979; Pillai et al 1982). …”

mentioning

confidence: 99%